Intelligence · Clinical Development
Pipeline search results
Programs matching “ophthalmic” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 35 pipeline programs matching "ophthalmic" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
0.05% Voclosporin Ophthalmic Solution (VOS)
Aurinia Pharmaceuticals
Dry Eye Syndrome
1 trial -
ADX-102 Ophthalmic Solution (0.5%)
Aldeyra Therapeutics
Non-infectious Anterior Uveitis
1 trial -
Aceclidine+Brimonidine combination ophthalmic solution
LENZ Therapeutics
Presbyopia
6 trials -
NN9535-4352
NovoThirteen
While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency
1 trial -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Allergic Conjunctivitis
4 trials -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Dry Eye
4 trials -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Dry Eye Disease
4 trials -
Reproxalap Ophthalmic Solution (0.25%) QID
Aldeyra Therapeutics
Dry Eye
1 trial -
Test - Bimatoprost 0.01% Ophthalmic Solution
Amneal Pharma Europe Ltd
Glaucoma, Open-Angle
1 trial -
bimatoprost ophthalmic solution formulation A
Allergan Pharmaceuticals International Limited
Glaucoma
1 trial -
ADX-102 Ophthalmic Drops (0.5%)
Aldeyra Therapeutics
Conjunctivitis, Allergic
1 trial -
ADX-102 Ophthalmic Solution (0.5%)
Aldeyra Therapeutics
Dry Eye Syndromes
1 trial -
FST-100 Ophthalmic Suspension
Takeda
Acute Adenoviral Conjunctivitis
1 trial -
Gatifloxacin 0.3% ophthalmic solution
Allergan Pharmaceuticals International Limited
Acute Bacterial Corneal Ulcers
1 trial -
NS2 Ophthalmic Drops (0.5%)
Aldeyra Therapeutics
Allergic Conjunctivitis
1 trial -
Nebivolol Ophthalmic Suspension 1 Percent
Summit Therapeutics
Open-Angle Glaucoma
1 trial -
Preservative-free, ophthalmic solution
Laboratoire HRA Pharma
Paediatric myopia
1 trial -
R348 Ophthalmic Solution, 0.2%
RIGEL PHARMACEUTICALS INC
Chronic Graft-versus-host Disease
1 trial -
R348 Ophthalmic Solution, 0.2%
RIGEL PHARMACEUTICALS INC
Keratoconjunctivitis Sicca
2 trials -
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Aldeyra Therapeutics
Dry Eye
1 trial -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Conjunctivitis, Allergic
1 trial -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Dry Eye Syndromes
1 trial -
Reproxalap Ophthalmic Solution (0.25%)
Aldeyra Therapeutics
Dry Eye Syndrome
1 trial -
Voclosporin Ophthalmic Solution
Aurinia Pharmaceuticals
Dry Eye
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.